ArticleJournal of clinical medicine2020
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- The Current Cardio-Oncology Landscape Across Australia.Current treatment options in oncology · 2026Review
- MiRNA Regulations in Cardiotoxicity Induced by Oncologic Therapies and Possible Immune Response.Current medicinal chemistry · 2026Review
- Prosthetic valve dysfunction post-bevacizumab: a transcatheter aortic valve replacement thrombosis case report.European heart journal. Case reports · 2025Article
- The cardio-oncology multidisciplinary team: beyond the basics.Cardio-oncology (London, England) · 2025Review
- Is lenvatinib-induced blood pressure elevation a favorable prognostic factor in patients with hepatocellular carcinoma?Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- The impact of different treatments on thromboelastography and other conventional parameters in patients with colorectal cancer.Discover oncology · 2024Article
- Investigating the effect of cancer medication in the development of Takotsubo cardiomyopathy.American journal of cardiovascular disease · 2024Review
- Influence of background cardiovascular risk factors on VEGF inhibitor-related adverse vascular events in patients with non-small cell lung cancer: a retrospective study.Journal of cancer research and clinical oncology · 2023Article
- Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system.Cardio-oncology (London, England) · 2023Article
- Safety Analysis of Bevacizumab in Ovarian Cancer Patients.Journal of clinical medicine · 2023Article
- Colon Cancer Pharmacogenetics: A Narrative Review.Pharmacy (Basel, Switzerland) · 2022Review
- Cancer Therapies and Vascular Toxicities.Current treatment options in oncology · 2022Review
- Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARγ signaling pathway.Annals of translational medicine · 2021Article
- Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis.Frontiers in cardiovascular medicine · 2021Review
- Human Platelets Take up Anti-VEGF Agents.Journal of ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.